Johnson & Johnson (JNJ) : Catawba Capital Management Va reduced its stake in Johnson & Johnson by 0.47% during the most recent quarter end. The investment management company now holds a total of 57,222 shares of Johnson & Johnson which is valued at $7,160,761 after selling 273 shares in Johnson & Johnson , the firm said in a disclosure report filed with the SEC on Jul 19, 2016.Johnson & Johnson makes up approximately 1.69% of Catawba Capital Management Va’s portfolio.
Other Hedge Funds, Including , Acadian Asset Management boosted its stake in JNJ in the latest quarter, The investment management firm added 99,947 additional shares and now holds a total of 550,200 shares of Johnson & Johnson which is valued at $68,852,028. Johnson & Johnson makes up approx 0.34% of Acadian Asset Management’s portfolio.Beech Hill Advisors reduced its stake in JNJ by selling 1,900 shares or 4.41% in the most recent quarter. The Hedge Fund company now holds 41,200 shares of JNJ which is valued at $5,155,768. Johnson & Johnson makes up approx 3.36% of Beech Hill Advisors’s portfolio.Cim reduced its stake in JNJ by selling 17 shares or 0.72% in the most recent quarter. The Hedge Fund company now holds 2,331 shares of JNJ which is valued at $287,039. Johnson & Johnson makes up approx 0.14% of Cim’s portfolio.Baxter Bros Inc reduced its stake in JNJ by selling 260 shares or 0.54% in the most recent quarter. The Hedge Fund company now holds 48,221 shares of JNJ which is valued at $5,923,950. Johnson & Johnson makes up approx 1.85% of Baxter Bros Inc’s portfolio.Needelman Asset Management Inc reduced its stake in JNJ by selling 15 shares or 0.13% in the most recent quarter. The Hedge Fund company now holds 11,465 shares of JNJ which is valued at $1,401,826. Johnson & Johnson makes up approx 4.03% of Needelman Asset Management Inc’s portfolio.
Johnson & Johnson closed down -0.11 points or -0.09% at $125.14 with 73,34,633 shares getting traded on Wednesday. Post opening the session at $125.84, the shares hit an intraday low of $125.04 and an intraday high of $126.07 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, Johnson & Johnson reported $1.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $1.68. The company had revenue of $18482.00 million for the quarter, compared to analysts expectations of $17985.80 million. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 EPS.
Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by UBS on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 137 from a previous price target of $126 .Company shares were Reiterated by RBC Capital Mkts on Jul 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 133 from a previous price target of $125 .Standpoint Research Initiated Johnson & Johnson on May 20, 2016 to “Sell”, Price Target of the shares are set at $94.
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.